Navigation Links
Sangamo BioSciences Announces Fourth Quarter and Full Year 2009 Conference Call and Webcast
Date:1/27/2010

g proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.

SOURCE Sangamo BioSciences, Inc.

RELATED LINKS
http://www.sangamo.com

'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Capnia, Inc. (NASDAQ: ... diagnostics based on its proprietary Sensalyze™ Technology Platform ... financial results for the third quarter and nine ... the completion of our initial public offering (IPO), ... recently initiated CoSense® commercial launch," said Anish Bhatnagar, ...
(Date:12/19/2014)... 18, 2014 Baptist Health Lexington is the first ... receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation status ... Atrial fibrillation is the most common cardiac arrhythmia and has ... can lead to stroke and possible death. More than 5 ... have atrial fibrillation and the numbers are rapidly increasing as ...
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... Nov. 5, 2011 Savient Pharmaceuticals, Inc. (NASDAQ: ... providing further clarity and context surrounding the risk ... occur with KRYSTEXXA® (pegloticase) in the treatment of ... at the American College of Rheumatology (ACR) Annual ...
... Volcano Corporation (NASDAQ: VOLC ), a ... designed to enhance the treatment of coronary and peripheral ... ( AD enosine V asodilator I ndependent ... by Volcano, will be presented in a Late-Breaking Session ...
Cached Medicine Technology:Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 2Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 3Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 4Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 5Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 6Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 7Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting 8Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 2Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 3Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011 4
(Date:12/19/2014)... 19, 2014 Surviving Mesothelioma says thousands of ... indicates that these pipes can leach asbestos into drinking water ... full story on the Surviving Mesothelioma website. , ... natural asbestos deposits, decaying water mains made of asbestos cement ... , To protect consumers from mesothelioma , water providers ...
(Date:12/19/2014)... Thompson HealthDay Reporter ... into the United States -- along with Angelina Jolie,s ... have highlighted cracks in the nation,s public health defense ... report released Thursday. Half of U.S. states are ... disease outbreaks. That was the main conclusion of the ...
(Date:12/19/2014)... LENEXA, Kan. (PRWEB) December 19, 2014 ... dedicated exclusively to healthcare providers, has been retained to ... for Johnson Memorial Hospital in Franklin, Ind. The top ... Smith has recently placed more than 900 healthcare executives ... 100-bed, county-owned, full service hospital providing care to the ...
(Date:12/19/2014)... 2014 Novellus Healthcare Communications, LLC ... & Clinics™, an independent journal that provides practical ... caring for patients inside the pharmacy and retail ... provide optimal access to quality care, Inside Patient ... the team treating and coordinating patient care in ...
(Date:12/19/2014)... 19, 2014 Pain Free Living a ... to announce a new Superior magnetic necklace ... are the strongest neodymium magnets for the fastest pain ... developed the Superior Magnetics brand for the fastest relief ... performs magnetic therapy using Superior Magnetic Jewelry at fairs ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:New Superior Magnetic Necklace Relieves Migraine Headache 2
... FACS today announced that Paphos Skincare of Ft Lauderdale, FL has finished ... in the World. The Cream is manufactured in Italy and sold worldwide ... ... -- Gary Weinberger, MD, FACS today announced that Paphos Skincare of Ft ...
... psychologists, geneticists and neuroscientists has reported that a safe ... the brain has improved spatial learning and working memory ... human use of the drug, the finding supports the ... cognitive impairment, cushion the cognitive impact of normal aging, ...
... product destroys fat cells while increasing muscle mass without a major decrease ... ... The Total Health and Rejuvenation Center have successfully used their new Hgh ... dieting. Sources at the Total Heath Center have released the preliminary results ...
... in the Feb. 1 issue of the journal SLEEP ... the longitudinal link between sleep problems and depression. Results of ... converse association was not found. These findings are consistent with ... children from the development of depression. , Results of ...
... plays a role, study suggests , , FRIDAY, Jan. 30 ... may be less likely to attempt suicide than others, ... analyzed data from almost 37,000 people who took part ... relationship between spirituality, religious worship and suicidal behavior. , ...
... small arteries at the surface of the brain redirects flow ... tissue starved of nutrients and oxygen following a stroke, a ... news," said David Kleinfeld, a physics professor at the University ... animal models of stroke. , Damage from stroke can continue ...
Cached Medicine News:Health News:The Only 100% Biologically Pure Lycopene Cream in the World 2Health News:Vascular drug found to improve learning and memory in middle-aged rats 2Health News:Study finds genetic link between sleep disorders and depression in young children 2Health News:Study finds genetic link between sleep disorders and depression in young children 3Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2
... Recommended for aqueous samples of moderate viscosity and density. Proven ergonomic ... greasing. Volume Range (ul) ... 1.0~2.0 Imprecision(%) ... Precision (ul) ...
... Digital offers improved ergonomics for today's ... modified grippy finger rest and the ... and efficiency. Finnpipette Digitals also feature ... mechanism (pat. pend.) and super blow-out ...
Inquire...
... Our variable volume Finnpipette Techpette ... a high performance pipette. Advanced ... volume range, ensures quality, safety, ... of the volume range is ...
Medicine Products: